27.6.2023
References
Avail advised Nordic Bioproducts Group on the EUR 30 million funding round by Taaleri’s bioindustry fund, Chilean CMPC and other investors
.jpg)
Avail advised Loisto Laboratoriot on the acquisition of an Espoo-based dental laboratory service provider Hammaslaboratorio Viphammas Oy. The acquisition further strengthens Loisto Laboratoriot’s services in the Helsinki metropolitan area both in terms of availability and service selection and supplements to Hammas Hohde’s dental clinics in the area.